Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

224
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
224
Errors occurring during blood pressure monitoring01:25

Errors occurring during blood pressure monitoring

661
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
661
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

247
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
247
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
168
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Social Determinants of Health and Continuous Glucose Monitoring Metrics in Type 1 or Type 2 Diabetes.

JAMA network open·2026
Same author

Mind the Performance Gap: Examining Dataset Shift During Prospective Validation.

Proceedings of machine learning research·2026
Same author

Off by a beat: the effects of temporal misalignment in reinforcement learning for sepsis treatment.

NPJ digital medicine·2026
Same author

Clinical trials for continuously monitored and updated AI systems.

Nature medicine·2026
Same author

Meals that heal: a randomized controlled trial testing the feasibility of commercial meal delivery as a convenient dietary intervention for depression.

Scientific reports·2026
Same author

Is AI actually improving healthcare?

Nature medicine·2026

Related Experiment Video

Updated: Jun 17, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Learning control-ready forecasters for Blood Glucose Management.

Harry Rubin-Falcone1, Joyce M Lee2, Jenna Wiens1

  • 1Division of Computer Science and Engineering, University of Michigan, 2260 Hayward St, Ann Arbor, 48109, MI, USA.

Computers in Biology and Medicine
|August 10, 2024
PubMed
Summary

A new machine learning algorithm for type 1 diabetes (T1D) management disentangles insulin and carbohydrate effects, improving blood glucose (BG) control. This method significantly enhances time in range compared to standard approaches.

Keywords:
Blood glucose managementMachine learningTime series forecastingType 1 diabetes

More Related Videos

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.0K
Author Spotlight: Streamlining Rice Breeding with CRISPR/Cas for Obtaining Optimal Phenotypic and Agronomic Traits
09:43

Author Spotlight: Streamlining Rice Breeding with CRISPR/Cas for Obtaining Optimal Phenotypic and Agronomic Traits

Published on: January 3, 2025

2.3K

Related Experiment Videos

Last Updated: Jun 17, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K
A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.0K
Author Spotlight: Streamlining Rice Breeding with CRISPR/Cas for Obtaining Optimal Phenotypic and Agronomic Traits
09:43

Author Spotlight: Streamlining Rice Breeding with CRISPR/Cas for Obtaining Optimal Phenotypic and Agronomic Traits

Published on: January 3, 2025

2.3K

Area of Science:

  • Biomedical Engineering
  • Artificial Intelligence in Medicine
  • Endocrinology

Background:

  • Type 1 diabetes (T1D) management requires diligent blood glucose (BG) monitoring and insulin dosing.
  • Current machine learning (ML) models for automated BG control struggle with accuracy due to entangled insulin and carbohydrate data.
  • Basal bolus (BB) insulin strategies often lead to inaccurate ML model training, hindering effective BG management.

Purpose of the Study:

  • To develop a novel algorithm for training BG forecasters that disentangles insulin and carbohydrate impacts.
  • To improve the accuracy and reliability of ML-based BG management systems for T1D patients.
  • To enhance automated insulin delivery systems through more precise BG prediction.

Main Methods:

  • Developed a new algorithm to disentangle insulin and carbohydrate effects on BG levels.
  • Utilized correction bolus values and the monotonic effect of insulin on BG for training.
  • Evaluated the algorithm using an FDA-approved simulator on 10 individuals over 30 days.
  • Assessed performance using proxy metrics on three real-world datasets.

Main Results:

  • The novel algorithm achieved an average time in range of 81.1% in simulations, significantly outperforming standard approaches (53.6%).
  • The method demonstrated reliable maintenance of healthy BG levels in simulated T1D individuals.
  • Proxy metrics indicated potential for improved control in real-world T1D datasets.

Conclusions:

  • The proposed algorithm effectively disentangles insulin and carbohydrate effects, leading to superior BG control in simulated T1D.
  • This advancement holds promise for developing more accurate and effective ML-based automated insulin delivery systems.
  • The findings pave the way for significant progress in ML-driven BG management for type 1 diabetes.